Samjin’s pyrimidinediones to enter Phase I clinical trials

Samjin Pharmaceutical, in collaboration with their drug development partner, the US based ImQuest Pharmaceutical Inc., have recently engaged in an effort to develop more active pyrimidinediones possessing this higher genetic barrier to resistance.

It is believed that these compounds will prolong the therapeutic utility of the pyrimidinediones by preventing HIV from easily evading the action...